Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation
Craig S. Schneider(Johns Hopkins University), Justin Hanes(Johns Hopkins University), Pichet Adstamongkonkul(Johns Hopkins University), Jung Soo Suk(Johns Hopkins University), Jane Chisholm(Johns Hopkins University), Laura M. Ensign(Johns Hopkins University), Benjamin C. Tang(Johns Hopkins University), Qingguo Xu(Virginia Commonwealth University), Andreas Henning(Johns Hopkins University), Sho-Yu S. Wang(Johns Hopkins University), Brian W. Simons(Johns Hopkins University), Xiaoqun Gong(Johns Hopkins University), Nicholas J. Boylan(Johns Hopkins University), Ethan Lee(Vanderbilt University), Michael Boyle(McMaster University), Tao Yu(Johns Hopkins University), Benjamin S. Schuster(Rutgers, The State University of New Jersey)
Cited by 308
Related Papers
Update on Key Emerging Challenges in Cystic Fibrosis
|Medical Principles and Practice|2014|3.7k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Multiattribute and Single-Attribute Utility Functions for the Health Utilities Index Mark 3 System
|Medical Care|2002|1.3k
Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis
|Science|1990|979
Inflammatory subtypes in asthma: Assessment and identification using induced sputum
|Respirology|2006|939